Community

Andrew Badrot

Chief Executive Officer, C2 Pharma

Andrew Badrot is the founder and CEO of C2 PHARMA, a Luxembourg-based pharmaceutical group that manufactures and distributes active pharmaceutical ingredients and complex chemical compounds obtained from natural and synthetic origins. He has more than 20 years of business experience across various industries. Andrew holds a MS in Financial Engineering from Stanford University, California, USA, and an Engineering degree in Nuclear Physics from Institut Polytechnique in France.

Contributions

Q: What do you think is the greatest lesson learned from the COVID-19 pandemic, and what lasting impacts do you foresee over the next 5–10 years?

Q: Although there is no such thing as a truly “crisis-proof” organization, how are you working to mitigate risks for future crises like the COVID-19 pandemic?

Q: What is your perspective on how the pharma industry has responded to the COVID-19 pandemic? What lessons have been learned?

Q: What two or three drug molecules do you identify as having had the greatest impact on society? What about on the pharmaceutical industry?

Q: How would you characterize the current landscape of M&A activity in the pharmaceutical/biopharmaceutical industry?

Q: What developing technologies do you believe will have the greatest impact on the biopharma industry in 2020 and beyond?